Actelion presents its Research and Development efforts - Building on a very strong pipeline.

(From Hugin)

ALLSCHWIL/BASEL, SWITZERLAND - 29 October 2003 - Actelion Ltd (SWX: ATLN) today provided a comprehensive overview of its preclinical and clinical pipeline at its R&D Day in London (UK). The company believes that its substantial efforts in drug discovery and clinical development are providing a strong and broad base for potential future growth. Actelion already has two orally available products on the market, Tracleer[R], approved for pulmonary arterial hypertension (PAH), and Zavesca[R], approved as the first oral treatment of type 1 Gaucher disease. Jean-Paul Clozel, MD and Chief Executive Officer at Actelion, said: "Our pipeline is the basis of Actelion's strategy of industrial growth. We have set ourselves the target to develop first-in-class drugs. We have highly professional and experienced teams at work in both drug discovery and clinical …